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There are several lines of evidence indicating a possible therapeutic action of cannabidiol
(CBD) in schizophrenia treatment. Studies with rodents have demonstrated that CBD
reverses MK-801 effects in prepulse inhibition (PPI) disruption, which may indicate
that CBD acts by improving sensorimotor gating deficits. In the present study, we
investigated the effects of CBD on a PPI learned response of capuchin monkeys
(Sapajus spp.). A total of seven monkeys were employed in this study. In Experiment
1, we evaluated the CBD (doses of 15, 30, 60 mg/kg, i.p.) effects on PPI. In Experiment
2, the effects of sub-chronic MK-801 (0.02 mg/kg, i.m.) on PPI were challenged by
a CBD pre-treatment. No changes in PPI response were observed after CBD-alone
administration. However, MK-801 increased the PPI response of our animals. CBD
pre-treatment blocked the PPI increase induced by MK-801. Our findings suggest that
CBD’s reversal of the MK-801 effects on PPI is unlikely to stem from a direct involvement
on sensorimotor mechanisms, but may possibly reflect its anxiolytic properties.
Keywords: cannabidiol (CBD), MK-801, monkey, prepulse inhibition, learning, memory
INTRODUCTION
Cannabidiol (CBD) is one of the several compounds extracted from the Cannabis plant reported
to have different therapeutic applications (Baker et al., 2003). These seem to include general
systemic anti-inflammatory (Mechoulam et al., 2002; Vilela et al., 2015) and antioxidant properties
(Hampson et al., 1998), as well as more specific effects in different neurological disorders, such as
epilepsy (Mechoulam et al., 2002), anxiety (Zuardi et al., 1982; Campos and Guimarães, 2008), and
schizophrenia (Zuardi et al., 1991; Leweke et al., 2012).
The antipsychotic effects, in particular, may result from the antagonistic action of CBD on
cannabinoid type 1 (CB1) and 2 receptors (CB2; Thomas et al., 2007). Zuardi et al. (2012)
suggested, however, that an interaction between CBD and anandamide is essential for the
psychoactive effect, considering that CBD also increases the availability of this endocannabinoid
via a reuptake inhibition mechanism (Mechoulam et al., 2002). The antipsychotic properties of
CBD have also been linked to changes in glutamate signaling that results from the activation of the
vanilloid TRPV type 1 receptor system. Anandamide (Di Marzo et al., 2001) and CBD (Cristino
et al., 2006) are both known TRPV1 receptor ligands, and the pre-synaptic activation of this
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system increases the release of glutamate in psychosis-related
areas of the brain (Xing and Li, 2007). Furthermore, CBD is
reported to reverse the prepulse inhibition (PPI) disruption
induced by the non-competitive glutamate NMDA receptor
antagonist dizocilpine (MK-801) in murine models (Long et al.,
2006; Gomes et al., 2014; Levin et al., 2014; however, see
Gururajan et al., 2011), with this effect being antagonized by the
TRPV1 receptor antagonist capsazepine (Long et al., 2006).
In fact, MK-801 has become a frequently used
pharmacological tool to induce schizophrenic-like symptoms in
pre-clinical experimental setups (Arai et al., 2008; Park et al.,
2014; Saletti et al., 2015). Schizophrenic patients commonly
demonstrate significant deficits in sensorimotor gating (Braff
et al., 2001). This dissociative anesthetic is also reported to
disrupt the PPI responding of rodents (Hoffman et al., 1993),
as well as to induce cognitive (Hikichi et al., 2013; Karamihalev
et al., 2014) and social recognition deficits (Yoshimi et al.,
2015) and hyperlocomotion (Park et al., 2014; Basurto et al.,
2015). However, to our knowledge, the effects of CBD on
the PPI response of non-human primates (NHP) have yet to
be assessed. It is known that manipulations of learning and
memory-related areas, such as the hippocampus, can alter PPI
responding (Kohl et al., 2013). Compared to rodents, NHPs have
a distinct motor response to cannabinoid-related substances
(Meschler et al., 2001) and display higher CB1 receptor densities
in memory-related areas (Ong and Mackie, 1999). So, here we
first analyzed the effects of CBD directly on the PPI response of
capuchin monkeys and then evaluated the influence of a CBD
pre-treatment on repeated MK-801-induced changes in the same
PPI test.
MATERIALS AND METHODS
Ethics Statement
All the procedures herein complied with the Brazilian regulations
for the scientific use of laboratory animals (Lei Arouca
11.794/2008), as well as the CONCEA/Brazil and NIH/USA
guidelines for the care and use of laboratory animals, and were
approved by the Animal Ethics Committee of the University of
Brasilia (no. 131791/2013).
Subjects and General Housing
Conditions
In total, seven capuchin monkeys (Sapajus spp.) were used, one
male and six females, weighing between 2.5 and 5.0 kg at the
beginning of the study. All subjects were housed and tested at
the Primate Center of the University of Brasilia, Brazil. They
were group or paired-housed under natural light, temperature
and humidity conditions in standard cages (3 m × 3 m × 1.8 m)
containing rope swings, nest boxes and natural substrate on the
floor. Fresh food was provided daily at 07:00 h, consisting of a
mixture of pieces of fruits and vegetables. Boiled eggs, nuts and
cooked chicken breast were given several times a week, also at
07:00 h. Unconsumed items were removed at 17:00 h, while water
and chow were available ad libitum.
Housing and maintenance conditions complied with the
regulations of the Brazilian National Institute of Environment
and Renewable Natural Resources (IBAMA). The animals were
only deprived of food and water during the specific trials
indicated in the procedure below. All subjects used had previous
experience with the PPI protocol (Saletti et al., 2014).
Startle Measurement and General
Procedure
Prepulse inhibition testing was performed in a transparent acrylic
chamber (60 cm × 30 cm × 30 cm) placed above a wooden
box (45 cm × 40 cm × 40 cm). Each subject was placed inside
this chamber in such a way that its head protruded through an
adjustable central neck hole located at the top. A transparent
acrylic device (30 cm × 30 cm × 25 cm) was placed directly
on top of the chamber, encompassing the subject’s head. This
device contained three speakers (model FT96H- frequency band
4 KHz∼30 KHz; Fostex, Japan), each located 10 cm from the
monkey’s head and connected to a sound generator (O’Hara &
Co., Ltd., Japan). One speaker was positioned on each side of the
animal’s head and generated the startle stimuli. The third speaker
was placed at the back of the device and emitted a constant
65dB white noise. An accelerometer (model BDK3; Inntechno
Japan Co.Ltd., Japan), connected to an amplifier (O’Hara & Co.,
Ltd., Japan), was placed at the bottom of the chamber. When
the subject was inside the chamber it stood on the accelerometer
platform. The accelerometer captured the animal’s whole-body
movement and transmitted the data to be recorded on the Animal
Startle software (PCI 6024E, developed by O’Hara & Co., Ltd.,
Japan) that interfaced with the Windows XP system (for details
see Saletti et al., 2014). A video camera (model #1004124; Clone,
Brazil) was connected to this experimental setup and monitored
the animal during each session.
Testing was conducted 5 days a week, between 8:00 and
12:00 h, in an acoustically isolated room located near the
monkeys’ home-cage. After a 10 min acclimatization period to the
test room and setup described above, PPI testing was conducted.
It consisted of 10 consecutive blocks of stimuli presentation, held
at 60 s intervals. During each block, three different stimuli were
randomly presented, also at 60 s intervals: a 115 dB pulse of
40 ms duration, an 80 dB prepulse of 20 ms duration and a
prepulse-pulse combination with a 120 ms interval between the
prepulse and pulse presentation. Stimuli intensity and duration
were based on previous studies (Saletti et al., 2014, 2015). The
startle response was recorded by the Animal Startle software
system that measured the animals’ body movements through
changes in force detected by the accelerometer. The animals’
body movements were recorded during a 600 ms post-stimuli
interval and the peak amplitude registered following the pulse or
prepulse+pulse stimulus of each trial was recorded as the startle
amplitude.
Experiment 1: Effects of CBD Treatment
on PPI
In the first experiment, CBD (0, 15, 30, and 60 mg/kg; volume
of 1 mL/kg; STI Pharm, UK) was dissolved in a 1:19 solution of
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Tween 80 (Sigma-Aldrich, Brazil) and 0.9% saline, respectively.
Doses were based on previous studies in rodents (Moreira and
Guimarães, 2005; Almeida et al., 2013; Levin et al., 2014).
For the safety of the personnel involved and to insure correct
intraperitoneal (ip) administrations, all animals were briefly
exposed to the anesthetic isoflurane via inhalation, yet an effective
anesthesia stage was never really attained.
All subjects were initially tested with vehicle and then treated
with the three doses of CBD. Only one treatment was given on
each test day, with a 2-week interval between trials. The order in
which the three CBD doses were given was randomly assigned
for each animal. Each subject received the vehicle injection or a
CDB dose and was then placed in the test chamber. After a 30 min
interval, it was submitted to the PPI test procedure described
above. Two females were excluded from the analyses due to data
recording problems, totalizing five animals in experiment 1 (one
male and four females).
Experiment 2: Effects of CBD
Pre-treatment Following Repeated
MK-801 Treatment
In this second experiment, the same seven monkeys were tested
4 months after the previous study. MK-801 (0.02 mg/kg; Sigma-
Aldrich, Brazil) and CBD (60 mg/kg; STI Pharm, UK) were both
dissolved in a 1:19 solution of Tween 80 (Sigma-Aldrich, Brazil)
and 0.9% saline, respectively. The former was administered
intramuscularly (im), whereas CBD was again given via ip route.
The injection volume of both substances was 1 ml/kg. The MK-
801 dose was based on our previous study (Saletti et al., 2015).
Each animal was given a MK-801 injection, once a week,
during three consecutive weeks. Twenty minutes after each
injection, the subject was tested in the same PPI procedure
described above. On the 4th week of testing, each monkey was
pre-treated with CBD and then 10 min later it received a MK-
801 treatment. PPI testing was once again held 20 min after
the MK-801 administration. Two weeks later, each animal was
injected with vehicle and following a 20 min interval tested in
the PPI protocol (VEH 2). To control for a habituation effect
due to repeated testing, and considering that the same monkeys
were used in both experiments, data from the vehicle trial of
Experiment 1 were used as a second control session in this study
(VEH 1).
Behavioral and Statistical Analysis
Data were expressed as the mean startle response or percentage
of PPI + standard error of the mean (+S.E.M.). The data were
normalized using the following calculation of the percentage of
inhibition (Saletti et al., 2014, 2015):
100∗(p− pp)
p
(1)
where p corresponds to the pulse-alone startle response and pp to
the prepulse+pulse response.
The data were normally distributed, according to the
Shapiro–Wilk test. To establish a possible between-treatment
effect (vehicle, MK-801 and CBD+MK-801) on the capuchins’
startle amplitude and percentage of PPI, data from each
experiment were analyzed using a one-way ANOVA for repeated
measures (pulse and prepulse+pulse trials were analyzed
separately). Whenever significant results were obtained, Fisher’s
LSD post hoc test was used for pair-wise comparison across
treatments. Significance level for all tests was set at p < 0.05.
For Shapiro–Wilk and ANOVA analysis we used the IBM
SPSS R© version 20 software. For comparisons with p < 0.05, we
also calculated the effect sizes (effsize) using Matlab software R©
(version R2013a).
RESULTS
Experiment 1: Effects of CBD Treatment
on PPI
In terms of the startle amplitude, a significant between-treatment
effect was not observed for either the pulse (F3,12 = 0.566,
p = 0.648; Figure 1A) or prepulse+pulse trials (F3,12 = 1,375;
FIGURE 1 | (A) Mean (+SEM) startle amplitude of the capuchin monkeys (n = 5) in the pulse (black bars) and prepulse-pulse trials (gray bars) following the vehicle
(VEH) and the three CBD treatments (15, 30, and 60 mg/kg). (B) Mean (+SEM) percentage of prepulse inhibition (PPI) of the capuchin monkeys (n = 5) following the
vehicle (VEH) and the three CBD treatments (15, 30, and 60 mg/kg).
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p = 0.297; Figure 1A), with the subjects’ response remaining
constant regardless of the treatment received. A similar profile
was seen for the percentage of PPI when analyzing the data
according to the treatment received (F3,12 = 0.368, p = 0.778;
Figure 1B) and over the course of the weeks of the experiment,
regardless of the specific treatment received (F3,12 = 1.283,
p= 0.325; Figure 2).
Experiment 2: Effects of CBD
Pre-treatment on MK-801-Induced
Changes in PPI
Among the different pulse (F5,30 = 1.270, p = 0.303;
Figure 3) or prepulse+pulse trials (F5,30 = 1.800, p = 0.143;
Figure 3), significant differences were not observed. However,
the percentage of PPI differed significantly between treatments
(F5,30 = 4.052, p = 0.006; Figure 4). This parameter was
significantly higher following all three MK-801 administrations,
compared to the first vehicle administration [vs. MK-801(1):
p = 0.009, effsize = 1.498; vs. MK-801(2): p = 0.026,
effsize = 0.983; vs. MK-801(3): p = 0.005, effsize = 1.743].
The percentage of PPI after the CDB+MK-801 treatment was
significantly lower than on the trials with only MK-801(1) and
MK-801(3), being similar to the levels seen following both vehicle
injections [vs. VEH 1: p = 0.183; vs. MK-801(1): p = 0.02,
effsize = 0.718; vs. MK-801(2): p = 0.512; vs. MK-801(3):
p= 0.013, effsize= 0.878; vs. VEH 2: p= 0.954].
DISCUSSION
CBD on Monkey PPI
The results from Experiment 1 indicated that the CBD
administration alone had no effect on the capuchin monkeys’
startle amplitude or PPI response. Although to our knowledge
this is the first study to evaluate such aspect in NHPs, similar
FIGURE 2 | Mean (±SEM) percentage of PPI of the capuchin monkeys
(n = 5) according to the week of Experiment 1, regardless of the CBD
dose received; VEH, vehicle.
FIGURE 3 | Mean (+SEM) startle amplitude of the capuchin monkeys
(n = 7) in the pulse (black bars) and prepulse-pulse trials (gray bars)
after vehicle administration (VEH 1), the injections of MK-801 (1–3)
held once a week during three consecutive weeks, the CDB
pre-treatment followed by a MK-801 treatment (CBD+MK801) held on
the 4th week, and the second vehicle administration (VEH 2)
performed on the 6th week. Except for VEH 1, held during Experiment 1, all
other data were recorded during Experiment 2.
FIGURE 4 | Mean (+SEM) percentage of PPI of the capuchin monkeys
(n = 7) following the vehicle administration (VEH 1), the injections of
MK-801 (1–3) held once a week during three consecutive weeks, the
CDB pre-treatment followed by a MK-801 treatment (CBD+MK801)
held on the 4th week, and the second vehicle administration (VEH 2)
performed on the 6th week. Except for VEH 1, held during Experiment 1, all
other data were obtained during Experiment 2. ∗p < 0.05 vs. VEH 1;
#p < 0.05 vs. CBD+MK-801.
results have been observed in rodents (Long et al., 2006; Gomes
et al., 2014; Levin et al., 2014; Pedrazzi et al., 2015). Long et al.
(2006) and Gururajan et al. (2011) reported, however, that a
systemic administration of CBD altered the startle response of
rodents. In this case, the percentage of PPI decreased following
a 10 mg/kg dose of CBD, whereas 3 and 30 mg/kg had no effect.
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This discrepancy may be partly due to species-specific
differences, as the CB1 receptor density of rodents and primates
differs in certain regions of the brain (Ong and Mackie, 1999), as
well as their motor response to cannabinoid-related substances
(Meschler et al., 2001). Important methodological aspects may
also have contributed. Due to ethical restrictions and reduced
sample size in monkey research, our subjects were submitted to
the PPI procedure in a repeated-exposure design. Nonetheless, a
temporal or drug-training effect does not seem to have influenced
the present result as the percentage of PPI remained constant
over the course of the procedure, regardless of the specific CBD
treatment given. Thus, our results in capuchins suggest that CB1
receptor antagonism may have no effect on sensorimotor gating
mechanisms.
CBD Pre-treatment on MK-801 Induced
PPI Enhancement
MK-801 has been shown to induce schizophrenic-like behaviors
in monkeys, such as deficits in memory-related processing
(Ogura and Aigner, 1993; Buffalo et al., 1994; Harder et al.,
1998; Harder and Ridley, 2000; Tsukada et al., 2005; Wang
et al., 2012) and more recently in changes in PPI responding
(Saletti et al., 2015). Although an acute 0.03 mg/kg dose of MK-
801 decreased the PPI of capuchin monkeys, repeated testing
(with different doses) in the same setup diminished this effect
possibly due to drug-induced ataxia or tolerance (Saletti et al.,
2015).
In the present study, we opted to use a lower dose of MK-
801 to reduce such levels of ataxia. The 0.02 mg/kg dose was
used in a repeated administration regimen, thereby leading to
an increase in the monkeys’ percentage of PPI. This result
differs from the MK-801-induced decrease in PPI reported in
rodents (Schulz et al., 2001; Gomes et al., 2014), considered to
be an indicator of a psychotic-like effect of this drug. It also
contrasts with the lack of effect observed for this dose in our
previous study using the same animals (Saletti et al., 2015).
In that instance, each subject received all possible treatments
only once (vehicle, 0.01, 0.02, and 0.03 mg/kg) in a pseudo-
randomized order, whereas only the 0.02 mg/kg dose was
presently given on three consecutive trials. Thus the present
increase in PPI, detected already on the first trial, seems unlikely
to be due to a habituation effect considering the 5-month
interval between the experiments, the similar PPI and startle
amplitude levels seen during the vehicle control trials of the
two studies (≈55% and 6 points, respectively), and the response
stability seen on the last session of current study (VEH 2
vs. CBD+MK801). Ketamine, another NMDA antagonist, is
also reported to increase the PPI response of healthy human
volunteers when using a brief inter-stimulus interval (Braff
et al., 2001; Duncan et al., 2001). The use of higher doses in
rodents and distinct hippocampal NMDA receptor sensitivity
could be important aspects contributing to the discrepancies
between human and rodent PPI responding (Duncan et al.,
2001). NMDA antagonists can block hippocampal long-term
potentiation, with this effect being modified by pre-training or
test familiarization through latent learning effect (Otnaess et al.,
1999; Ennaceur et al., 2011). The hippocampus is also known
to be responsable for PPI response modulation (Kohl et al.,
2013).
Interestingly, pre-treatment with CBD prevented the MK-801-
induced increase in the monkeys’ PPI. Considering the large
effect sizes values found (≈0.8 or more; Sullivan and Feinn, 2012),
we are able to conclude that the difference between the treatments
is expressive. Nonetheless, the effects induced by both MK-801
and CBD seem related to their anxiogenic and anxiolytic profiles,
respectively – an aspect that is highly relevant in the context of a
startle response. In mice, MK-801 is reported to increase anxiety
levels (Ennaceur et al., 2011), whereas CBD has been frequently
linked to anxiolysis (Zuardi et al., 1982; Guimarães et al., 1990;
Campos and Guimarães, 2008; Almeida et al., 2013). CBD seems
to activate serotoninergic 5-HT1A receptors (Russo et al., 2005;
Resstel et al., 2009; Soares et al., 2010; Gomes et al., 2011) and
attenuate cardiovascular and/or behavioral responses associated
with anxiety and panic in rats (Resstel et al., 2009; Soares et al.,
2010).
Although CBD has been reported to reverse the PPI disruption
induced by MK-801 (Long et al., 2006; Gomes et al., 2014)
and amphetamine in rodents (Pedrazzi et al., 2015), our present
results with capuchins fail to corroborate a possible anti-
psychotic effect for this compound in the context of sensorimotor
gating. In the presence of only MK-801, the startle amplitude
generally tended to decrease in the ‘pulse’ trials, yet increase in
‘prepulse+pulse’ trials. The latter, however, was also observed
with subsequent treatments (CBD+MK-801 and VEH 2). The
pre-treatment of the monkeys with CBD reversed this increase
tendency in startle amplitude in PPI, with no visible changes
in ‘pulse’ trials. Altogether, these results suggest that the CBD
effects on PPI are unlikely to stem from a direct involvement
in sensorimotor gating mechanisms. We suggest that the CBD-
induced reversal of the MK-801 effects may be related to their
anxiolytic and anxiogenic profiles, respectively (Zuardi et al.,
1982; Ennaceur et al., 2011; Almeida et al., 2013), although this
aspect was not directly investigated in the present study. Further
studies are necessary to better elucidate the interplay between
anxiety and schizophrenia, as well as the potential use of CBD
as an antipsychotic drug, possibly using other NHP models as
well.
CONCLUSION
In the present study, CBD alone had no effect on the PPI response
of capuchin monkeys, yet blocked the increase in this response
that was induced by NMDA receptor antagonism (MK-801). This
effect may stem from a general anxiolytic rather than an anti-
psychotic effect, corroborating an anxiolytic profile of CBD in the
PPI paradigm.
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